In our drug screen, we identified 5 potential combinatorial leads (PLX8394, bafetinib, ponatinib, VU6015929, and DDR1 7rh) with EGFR inhibitors (lapatinib and afatinib); bafetinib and ponatinib showed the best response in all COAD lines, independent of KRAS mutation type. This evidence concerns the gene EGFR and colon adenocarcinoma.